Great. Thanks, Steve. Looking at the macro environment, the VC industry is finding solid footing as a disruption caused by the recent banking crisis continues to be absorbed by the financial community. Venture capital dry powder in the U.S. remains at record levels with experts estimating there's more than a half a trillion dollars of capital ready to be deployed. In the second quarter, total VC industry investments were $40 billion, which is higher than pre-2021 investment levels. We're seeing the companies with the right team, technology and market continue to receive financing, albeit at many at lower valuations. Even though, we would prefer that our portfolio companies receive higher valuations, equity support at any valuation is an overall positive for Trinity and its portfolio. As a proof point, year-to-date, 30 of our portfolio companies have received more than $1.4 billion of new equity fundings. Debt financing such as Trinity's provides a crucial solution to the current market for venture-backed companies that want to continue to fund growth without major dilution. The evolving competitive landscape has been real favorable for Trinity, with volatility in the banking industry, creating outsized opportunities for non-bank solutions like us. We're seeing more opportunities at the top of the pipeline, but a smaller percentage of deals are being approved as we remain vigilant and adhering to our proven underwriting process. We are committed to continuing to execute the rigorous diligence process that is foundational to our business model. We've had a very exciting first half of the year, and as part of our growth strategy, we announced several important updates in the second quarter, including many new items surrounding our life science vertical. We believe that the life science industry holds immense potential for growth as we continue to make investments to capitalize on the opportunities we see in the sector. In early 2022, Trinity brought on Rob Lake, a seasoned professional with more than two decades of experience as Senior Managing Director to spearhead our growth efforts in the life science sector. Since then, the proportion of our assets under our management dedicated to life science investments has continued to grow. With a portfolio now totaling over $100 million. This quarter, we added to the team with the appointment of Igor DaCruz as Managing Director who brings more than 12 years of experience in the industry. We also announced a new office location in San Diego, designed to support the company's ongoing expansion in the sector, a city known for its disruptive research and innovation, the strategic hub now places Trinity at the heart of major life science hub. Additionally, we're expanding our tech lending platform's presence on the east coast with the addition of Andrew Ghannam, as Managing Director based in Manhattan. Andrew brings more than a decade of experience lending the venture-backed technology companies with $31 billion of venture capital investment last year. New York is a key market for Trinity on a go forward basis. We're building a unique internally managed BDC platform and an executing initiatives that support our ability to grow and deploy capital both on and off balance sheet. In the second quarter, we continue to realize the benefits of our direct lending joint venture and expanded our lending capacity with the addition of a credit facility with KeyBank. This off balance sheet growth provides incremental returns that flow to our shareholders. During the second quarter, we added $0.02 per share to our net investment income from our joint venture fees, and that's just the beginning. We intend to significantly ramp up our off balance sheet activity and deployment and assets under management. Trinity's newly formed RIA has also engaged with several potential investment partners and we expect to have more to announce on that strategy over the next several quarters. Gross fundings in Q2 are approximately $155 million. And proceeds received from repayments of the company's debt Investments during Q2 totaled approximately $104 million. The composition of our portfolio remains consistent with prior quarters and shows diversification across 19 different industries. We have intentionally constructed a portfolio with varied industry segmentation with our largest industry exposure, representing only 12% of the portfolio at cost. Additionally, our pipeline is robust. We finished the quarter with $345 million of unfunded commitments, all of which are subject to milestones, ongoing diligence and approval by our investment committee. In addition, we had signed term sheets in the quarter of $157 million at the end of Q2. As we look to the second half of the year, we believe companies will continue to seek alternative lending solutions. We intend to be the go-to solution and lender for growth stage companies providing all financing solutions with the exception of the inexpensive receivable financing that they can get from banks. Our team is built an attractive platform to support the needs of growth stage companies and the unique partnerships we maintain with current and prospective portfolio companies is unmatched. We are well positioned to continue to profitably grow this business. And as we increase our off balance sheet activity, we will see new ways to improve returns for our shareholders. As an internally managed BDC, we are focused on return on equity and delivering a steady dividend to our shareholders. We've been real consistent with that messaging from day one, our efforts on and off balance sheet are to generate outsize ROE for our shareholders. Trinity will continue to seek opportunities to further diversify our capital base with access to both public and private markets as we drive value for our shareholders. Our CFO, David Lund will now discuss our operating performance in more detail. Dave?